Universal Vision Biotechnology (3218) reported revenue of NT$376.8 million for Oct 2026, +8.7% year on year and +4.9% from the previous month. Revenue for Jan–Oct 2026 was NT$3.75 billion (+6.7% year on year).
Year-on-year revenue growth: 9 months in a row. →
In Oct 2026, it ranked No. 24 by revenue among 160 Biotech & Medical companies.
Monthly revenue chart
Hover over (or tap) a bar to see that month’s revenue.
Monthly revenue history
| Month | Revenue | YoY | MoM |
|---|---|---|---|
| Oct 2026 | NT$376.8 million | +8.7% | +4.9% |
| Sep 2026 | NT$359.3 million | +11.5% | -9.3% |
| Aug 2026 | NT$396.3 million | +9.4% | -2.3% |
| Jul 2026 | NT$405.8 million | +19.3% | +8.1% |
| Jun 2026 | NT$375.4 million | +17.1% | +1.2% |
| May 2026 | NT$370.7 million | +6.6% | -2.5% |
| Apr 2026 | NT$380.4 million | +7.3% | +3.2% |
| Mar 2026 | NT$368.6 million | +1.4% | +4.2% |
| Feb 2026 | NT$353.8 million | +3.3% | -3.7% |
| Jan 2026 | NT$367.4 million | -11.9% | -0.2% |
| Dec 2025 | NT$368.1 million | +3.2% | +15.6% |
| Nov 2025 | NT$318.5 million | -4.2% | -8.1% |
| Oct 2025 | NT$346.6 million | -0.7% | +7.5% |
| Sep 2025 | NT$322.3 million | -0.4% | -11.0% |
| Aug 2025 | NT$362.3 million | -8.1% | +6.6% |
| Jul 2025 | NT$340.1 million | -6.0% | +6.1% |
| Jun 2025 | NT$320.6 million | -5.2% | -7.8% |
| May 2025 | NT$347.7 million | +1.4% | -1.9% |
| Apr 2025 | NT$354.6 million | -1.1% | -2.4% |
| Mar 2025 | NT$363.5 million | -1.8% | +6.2% |
| Feb 2025 | NT$342.4 million | +0.1% | -17.9% |
| Jan 2025 | NT$417.3 million | +16.3% | +17.0% |
| Dec 2024 | NT$356.5 million | +5.8% | +7.2% |
| Nov 2024 | NT$332.5 million | +4.3% | -4.8% |
| Oct 2024 | NT$349.1 million | +3.6% | +7.9% |
Jan–Oct 2026 cumulative: NT$3.75 billion (+6.7% YoY)
Other Biotech & Medical companies
Compare with peers: Universal Vision Biotechnology vs PEC / Universal Vision Biotechnology vs Lotus Pharm / Universal Vision Biotechnology vs Bora
| Company | Revenue | YoY |
|---|---|---|
| PEC | NT$2.84 billion | +102.0% |
| Lotus Pharm | NT$2.13 billion | -22.5% |
| Bora | NT$1.99 billion | +15.9% |
| Great Tree Pharmacy | NT$1.67 billion | +1.5% |
| EXCELSIOR | NT$1.02 billion | +38.6% |
| PEGAVISION | NT$793 million | +13.0% |
| Synmosa Biopharma | NT$766.6 million | +41.2% |
| Y.S.H. | NT$749.4 million | +4.4% |
See also
← All Taiwan listed & OTC companies
Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16